Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Convertible Debt (2016 - 2023)

Protalix BioTherapeutics (PLX) has 11 years of Convertible Debt data on record, last reported at $20.4 million in Q4 2023.

  • For Q4 2023, Convertible Debt fell 27.56% year-over-year to $20.4 million; the TTM value through Dec 2023 reached $20.4 million, down 27.56%, while the annual FY2023 figure was $20.4 million, 27.56% down from the prior year.
  • Convertible Debt reached $20.4 million in Q4 2023 per PLX's latest filing, up from $20.1 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $53.5 million in Q3 2020 and bottomed at $20.1 million in Q2 2023.
  • Average Convertible Debt over 5 years is $37.1 million, with a median of $28.2 million recorded in 2022.
  • Peak YoY movement for Convertible Debt: rose 6.66% in 2020, then crashed 48.01% in 2021.
  • A 5-year view of Convertible Debt shows it stood at $51.0 million in 2019, then increased by 5.0% to $53.5 million in 2020, then tumbled by 47.88% to $27.9 million in 2021, then increased by 1.08% to $28.2 million in 2022, then dropped by 27.56% to $20.4 million in 2023.
  • Per Business Quant database, its latest 3 readings for Convertible Debt were $20.4 million in Q4 2023, $20.1 million in Q2 2023, and $28.3 million in Q1 2023.